Jiejie Zhuang1,2,3†
Xiaqing Ma- 1Department of Anesthesiology, Suzhou Hospital of Anhui Medical University, Suzhou, China
- 2Department of Nursing, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
- 3Kangda College of Nanjing Medical University, LianYunGang, China
- 4Department of Anesthesiology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China
Chronic musculoskeletal pain (CMP) is the most common type of chronic pain, defined as persistent or recurrent pain condition deriving from musculoskeletal structures such as muscles, joints or bones that lasts for more than 3 months. CMP is multifactorial and severely affects people's quality of life. CMP may be influenced by a number of factors, including contextual factors, the presence of comorbidities, arthritis coping efficacy and access to CMP care. To deepen the comprehensive understanding of CMP, this narrative review provides the latest literature on disease classification, clinical diagnosis, treatment and basic research. In terms of the classification of the disease, here we introduce the 11th edition of the International Classification of Diseases (IDC-11), in which CMP is divided into chronic primary musculoskeletal pain and chronic secondary musculoskeletal pain. In the clinical diagnosis section, the progress of central sensitization in the diagnosis of CMP will also be summarized. In addition, we summarize some recent advances in clinical treatment and basic research.
Introduction
CMP involves more than 150 diseases of the human motor system, including common chronic joint pain, neck and shoulder pain, low back pain, limb pain, spinal pain, fibromyalgia and myofasciitis. Musculoskeletal disorders affect 20 to 33% of the global population. Although the prevalence of CMP reported in various literatures is inconsistent, it is certain that it increases with age, among which low back pain is the most common, with an incidence of 30–40% in adults. A recent report in the United States indicates that one in two adults has CMP, which is equivalent to the incidence of cardiovascular disease and chronic respiratory disease combined.
Despite the prevalence and impact of CMP, as well as the proliferation of new therapies, CMP is still a major challenge to clinical and basic research. There are many kinds of CMPs, and the pathogenesis of different diseases if different, which may involve one or more of inflammatory responses, fibrosis, release of neurotransmitters, abnormal changes in neuroimmunity, peripheral sensitization and central sensitization.
Pain is the most common symptom of CMP and the most critical factor in the burden of the disease. Chronic pain not only seriously affect the daily life of patients, but tends to develop into depression, which further causes the refractory CMP. Therefore, in order to better treat CMP, it is not only necessary to understand the specific etiology of the disease, to treat the cause of the disease, but also to carry out corresponding symptomatic treatment, whether physical or psychological symptoms. The newly released IDC-11 divided CMP into primary and secondary, which provided a new direction for better understanding of the etiology, diagnosis and treatment of CMP.
The Classification of Chronic Musculoskeletal Pain
In the 10th edition of the International Classification of Diseases (ICD-10), symptoms associated with known pathological conditions affecting the musculoskeletal system or connective tissue or unknown pathologies at specific locations are collectively referred to as musculoskeletal pain. The former is common as osteoarthritis (OA), autoimmune inflammatory arthritis (RA). “Back pain” or “periarticular pain” fall into the more common category of the latter. According to the ICD-10, pain with a known cause is assigned to the diagnostic code for the disease, not the pain code. However, for patients who seek help primarily to relieve pain rather than treat an underlying condition, a pain code would ideally be assigned. Whereas, in ICD-10, composite code is not part of the coding strategy.
The ICD-11 split CMPs into two main types: chronic primary musculoskeletal pain and chronic secondary musculoskeletal pain (1). Chronic primary musculoskeletal pain is defined as chronic pain experienced in muscles, bones, joints, or tendons comorbid with significant emotional distress or functional disability, and cannot be attributed directly to a known disease or damage process, such as chronic non-specific low back pain and chronic widespread pain.
Chronic secondary musculoskeletal pain is a kind of CMP arising from a known disease and is commonly due to several main causes: ① persistent local or systemic inflammatory diseases caused by crystal deposition, infection, autoimmune or autoinflammatory processes; ② local musculoskeletal structural changes; ③ musculoskeletal problems caused by neurological diseases, such as muscular hypertonicity in Parkinson disease.
This new classification combines the underlying mechanisms of chronic pain with early musculoskeletal disorders to provide a more accurate epidemiological analyses of diseases characterized by musculoskeletal pain. The change in classification will allow for patient-centered management, not just pathophysiology driven by disease, and will mean the need for multimodal treatment of chronic pain.
The Assessment of Musculoskeletal Pain
Diagnosis of CMP requires a detailed history, careful physical examination, and careful laboratory and imaging tests to rule out infections, tumors, and other diseases. What's more, once CMP is diagnosed, it is also important to assess the pain and related conditions, which is conducive to the diagnosis of the disease and the determination of treatment plan. Since the occurrence of CMP is believed to be closely related to the occurrence of central sensitization, the progress of central sensitization in the diagnosis of CMP will also be summarized here.
The Assessment of the Pain Intensity
The most commonly used assessment tools for pain intensity include the Numerical Rating Scales (NRS), Verbal Rating Scales (VRS), Visual Analog Scales (VAS), and the Faces Pain Scale-Revised (FPS-R) (2, 3). In clinical, we can choose an appropriate assessment method according to the specific situation of the patient. NRS is a method for patients to describe their pain intensity on a scale of 0–10, which is more suitable for patients with less education and understanding. When assessed using VRS, patients are asked to choose from a list of words (no pain, mild pain, moderate pain, severe pain, extreme pain) that better describe their pain intensity. This method is easy to understand, but it is more suitable for history-taking and follow-up because different patients have different comprehension for adjectives. When using the VAS method, a 10 cm ruler should be prepared in advance, with the 0 cm end representing no pain and the 10 cm end representing unbearable severe pain, and then patients should choose a length representing their pain intensity. This is also a common evaluation method in clinical practice. But the results may vary greatly with patient's cognitive ability, level of education and comprehension. For patients such as elderly, infants and other groups, who cannot evaluate the intensity of pain with NRS, VRS or VSA, we can judge by some pain-related behavioral changes. FPS-R is the commonly used method, which is especially suitable for children.
Another common way to assess the pain intensity is through questionnaires, and the McGill Pain Questionnaire is the most classic and comprehensive questionnaire used in clinical practice (4). The questionnaire involves not only the intensity of the pain, but also the character of the pain. It contains a number of words describing pain that are grouped into four categories: feeling, emotion, evaluation and miscellaneous.
Contextual Factors and Psychological Assessment
As with other chronic pain conditions, several key contextual factors can influence pain perception during CMP. These include the presence of comorbid health problems (5, 6), social support (7, 8), sex/gender (9), education and heath literacy, income, personality. This explains why people with radiologically similar arthritis severity may experience varying degree of pain or other chief complaint experience (9). Thus, CMP assessment requires a bio-psychosocial perspective including not only the assessment of pain, but also its downstream effects and contextual factors. Clinically, GAD-7, PHQ-9 and PHQ-15 scales are commonly used to evaluate the existence and degree of psychological disorders in patients (10, 11).
Function Assessment
The Short Form 36 (SF-36) is commonly used to evaluate the function of CMP patients. The SF-36 is a self-administered universal measure of health-related quality of life (QoL) that focuses on both physical and mental aspects. It includes 36 projects in eight health areas. The total Likert scale was used in this health survey. The scores are eventually translated to 0–100, with a higher score representing a better health-related QoL.
In trials of OA, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is the most commonly used outcome measure to evaluate symptoms (12). Another questionnaire often used is the Nordic Standardized Musculoskeletal Symptoms Questionnaire (NMQ) (13).
The Assessment of Central Sensitization in CMP
A distinct feature of CMP is central sensitization, which is defined as increased reactivity of nociceptive neurons, such as increased excitability, enhanced synaptic transmission, and reduced inhibition in the central nervous system (CNS) to normal input. So far, there are no objective indicators of central sensitization in vivo, but some signs and symptoms may be suggestive in clinical practice.
Quantitative sensory testing (QST) is a clinical surrogate marker for central sensitization that comprehensively assesses sensitivity to a range of stimuli, especially enhanced reactivity (14). QST is a promising method for detecting central sensitization, but it could only evaluate evoked responses, not spontaneous pain. The successful use of QST relies primarily on testing skin sensitivity, rather than deep pain arising from deep tissues. Dynamic mechanical ectopic allodynia can be examined by brushing the skin. This could be a manifestation of central sensitization, but may also be caused by peripheral drives (15). Further research is needed to apply objective markers of central sensitization, such as biomarkers and functional neuroimaging, into clinical practice.
The Treatment of Chronic Musculoskeletal Pain
CMP is still a huge challenge for both clinicians and researchers. It is widely believed that the burden of CMP will continue to increase (16) as populations age and the global obesity epidemic increases. The main objectives of CMP treatment are to relieve pain, improve function and improve quality of life. The chronic primary musculoskeletal pain is more common in primary care, but as management progresses, many are subclassified as chronic secondary musculoskeletal pain. Chronic secondary musculoskeletal pain is a kind of CMP arising from a known disease and is commonly due to several main causes, so the treatment can be more inclined to the etiological treatment. At present, in clinical practice, the mainstream treatment method is the combination of pharmacological and non-pharmacological approaches, and assisted by exercise, weight reduction and education of multi-mode treatment (17). Analgesic or surgical interventions are recommended (18, 19) based on disease severity and joint site.
Pharmacological Therapy for CMPs
There are many options available for treatment of CMP, however, pharmacological remains the mainstay. This part will provide an overview for clinicians of recent advances in knowledge on the use of existing pharmacological therapies for CMPs.
Non-opioid Analgesics Therapy for CMPs
NSAIDs
NSAIDs are a class of non-steroidal drugs that have antipyretic and analgesic effects by inhibiting the activity of cyclooxygenase (COX) and then reducing the synthesis of prostaglandins (20). Although NSAIDs have a good analgesic effect on mild to moderate CMP caused by inflammatory factors, their therapeutic effect also has a ceiling effect. Therefore, increasing dose and the combined use of two NSAIDs drugs should be avoided in clinical use.
NSAIDs can be classified into non-selective COX inhibitors and selective COX-2 inhibitors according to their selectivity for cyclooxygenase subtypes. The two classes of NSAIDs have their own adverse reactions. Non-selective COX inhibitors are more harmful to gastrointestinal mucosa, while selective COX-2 inhibitors are more likely to cause cardiovascular and renal adverse reactions (21). Therefore, NSAIDs should be used with caution or avoided in patients with a history of upper gastrointestinal ulcer, kidney disease or ischemic heart disease.
Cannabis-Based Medicines
It has been speculated that dysfunction of the endocannabinoid system may be one of the causes of persistent pain in osteoarthritis (22–24). As traditional treatments for CMPs are imperfect, treatment options such as cannabis-based medicines may hold promise.
Studies show that the most common reason that patients are using medical cannabis (MC) if for management CMP (25). Chronic low back pain, as a common musculoskeletal disorder, is one of the most common reasons patients consult in primary care. Fearful of the many side effects of opioid use, many patients may turn to MC for effect. However, evidence on MC as a treatment of CMP is still lacking.
An 8-week cross-over RCT study of spinal pain and headache showed that the intensity of spinal pain was significantly lower in the nabilone group than in the placebo group. Moreover, participants generally preferred nabilone to placebo during the medication switch period (26). In a retrospective cohort study of 61 patients who use prescription opioids, almost half of the patients think of the use of MC can reduce the use of prescription opioids, however, also found at the same time, the only way to stop the use of opioids is higher doses of cannabinoid, with the adverse event also increases (27).
Although MC has been shown to be effective in many chronic pain models, risks should be weighed against those of other current treatments, such as opioids.
Serotonin-Noradrenaline Reuptake Inhibitor (SNRIs)
SNRIs, represented by duloxetine and venlafaxine, are commonly used clinically as a class of antidepressant drugs. Studies have shown that SNRIs have significant analgesic and antidepressant effects on various kinds of chronic musculoskeletal pain (28, 29). The mechanism of SNRIs alleviating CMP pain mainly involves enhancing the role of the descending inhibitory system and reducing the pain stimulation signals transmitted through the spinal cord.
The 2014 Guidelines for the Treatment of Knee Osteoarthritis issued by the Osteoarthritis Research Society International (OARSI) are the first to include duloxetine as a recommended treatment. Studies have shown that duloxetine is more effective in combination with NSAIDs and has additional benefits for patients with concurrent depressive symptoms (30, 31). Other studies have shown that duloxetine has a direct analgesic effect in the treatment of pain, rather than just antidepressant effect (32). The cause of fibromyalgia, which is characterized by widespread pain in muscles and soft tissues throughout the body, remains unknown. Studies have shown that duloxetine can significantly reduce the pain scores of patients with fibromyalgia, regardless of depression (33).
Compared with NSAIDs, SNRIs has a good safety profile in gastrointestinal and cardiovascular adverse events, but there are some unavoidable side effects such as nausea, dizziness, constipation, and loss of appetite.
Muscle Relaxant
Muscle relaxants used in clinical practice can be classified into two types: skeletal muscle relaxant (baclofen, dantrolene) and central muscle relaxant (benzodiazepines, non-benzodiazepines, tizanidine).
Ion Channel Drugs
Clinical ion channel agents include sodium channel blockers (such as carbamazepine, oxcarbazepine, lidocaine, etc.), calcium channel modulators (such as gabapentin, pregabalin) and potassium channel openers [flupirtine, have been withdrawn from the market due to its hepatotoxicity (34)]. Calcium channel modulators are most widely used in CMP. The main mechanisms by which calcium channel blocker relieve pain are: inhibition of calcium influx and reduction of neurotransmitter release, thereby reducing abnormal excitation of pain transduction pathways (35).
Topical Drugs
Topical non-opioid analgesics for the treatment of CMP include NSAIDs, local anesthetics, capsaicin, and traditional Chinese medicines (TCMs). Topical drugs can directly penetrate into the affected tissue through the skin to play an analgesic effect. It has the advantages of fast acting, high local concentration, less systemic exposure and fewer adverse reactions. Compared with oral preparations, topical drugs are more suitable for long-term CMP management (33, 36, 37).
Opioid Therapy for CMPs
As one of the leading causes of disability, osteoarthritis affects more than 500 million people worldwide (38). Basic treatments for OA include exercise and maintaining a healthy weight, as well as analgesics based on NSAIDS and acetaminophen. However, the role of opioid analgesics in the treatment of OA varies from country to country (37, 38). In the United States, approximately 40% of patients with knee osteoarthritis use opioids (39).
A recent review evaluated the efficacy and safety of opioid analgesic regimens in patients with osteoarthritis. The researchers found that the pain and disability benefits of opioids in patients with osteoarthritis were minimal, but they may increase the risk of adverse events (40).
Non-pharmacological Management of CMPs
Acupuncture Treatment for CMPs
Available evidence indicates that acupuncture may be a safe option for providing short-term pain relief in the treatment of knee osteoarthritis (41, 42) and chronic low back pain (43). Other studies have shown that acupuncture is also beneficial for fibromyalgia (44). However, there is a lack of positive evidence regarding the use of acupuncture in osteoarthritis of the hip and rheumatoid arthritis (45).
Local Anesthetic Injection for CMPs
Local anesthesia options for the treatment of CMP include paracetamol (acetaminophen) and intraarticular corticosteroid injections if pain is moderate to severe (17). However, the guidelines indicate that the clinical and economic evidence for intra-articular corticosteroid injections is limited and that the available evidence is inconsistent (17). Additional results suggest that intraarticular corticosteroid injections may be used in osteoarthritis of the knee, but not in osteoarthritis of the hip (46).
Recommendations for Lifestyle Improvements in People With CMPs
Physical activity (including exercise) is the cornerstone of the treatment of musculoskeletal pain (47, 48). To evaluate the beneficial of physical activity on strength, flexibility and cardiovascular fitness in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis, a systematic review and meta-analysis were performed in 2018. According to the systematic review, the European League Against Rheumatism (EULAR) recommended physical activity for people with inflammatory arthritis and OA (49). Unfortunately, little is known about the best dose and type of exercise, especially whether exercise is better with or without pain. A recent systematic review of pain-exercise vs. pain-free exercise for CMP found that a pain-exercise regimen had a small but statistically significant short-term benefit over pain-free exercise (50). When exercise is painful, the immune system and the affective aspects of pain may provide some additional benefits. These mechanisms can alleviate and relieve musculoskeletal pain and, with appropriate clinical support and education, redefine pain as safe, non-threatening exercise. In addition, allowing painful exercise can lead to greater load/amount of movement, thus promoting functional recovery.
Since weight load is closely related to exercise, weight loss and obesity should be considered as a strategy to benefit global health, especially for CPM patients. The data from over 400 published reviews and original articles suggests that across he seven musculoskeletal diseases (osteoarthritis, rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, psoriatic arthritis, systemic sclerosis and gout), moderate-quality evidence suggested that he heavier a patient was, the overall prognosis, including pain, function and activity, was worse (51).
In conclusion, given the beneficial effects of exercise on numerous outcomes, sufficient amounts of exercise are recommended. Furthermore, Also, a healthy lifestyle and an appropriate weight are recommended to avoid the negative consequences of being overweight.
Multimodal Chronic Pain Therapy for CMP
Due to the COVID-19 pandemic, many CMP patients are unable to see their doctors regularly in person. In response to this situation, a randomized controlled clinical trial has been conducted, which shows that app-based mobile multidimensional therapy improved catastrophizing, quality of life, and mental flexibility immediately after treatment in adults with CMP, and the main outcome of catastrophizing remained effective at least 3 months following treatment. In addition, they can promote self-management and can be used to complement face-to-face pain treatments (52).
Another interesting exploratory randomized controlled trial was to observe the preliminary effectiveness of an immersive virtual reality (VR) multimodal therapy for older adults with chronic back pain (CBP) in a laboratory setting over a period of four weeks. It showed that only a significant improvement in the subjective functional capacity after the completion of a four-week multimodal pain therapy in VR. There were no significant differences in ear-avoidance beliefs and general physical and mental health. Although VR therapy did not achieve the reduction in pain intensity achieved by traditional multimodal pain therapy, the results of this study suggest that current VR therapy can achieve the reduction in pain intensity. In general, it would be considered as an adjunctive therapy for multimodal pain management, but cannot be used as a substitute in its current prototype (53).
From Basic Research to Clinical Administration
CMP is a multifactorial disease and not all patients with CMP have the same symptoms or rate of disease progression. This has led to disagreement (or lack of consensus) in the community about the drivers of CMP progression and pain. However, to date, it has been thought to involve a number of components stemming from central processing dysfunction, including central sensitization and impaired processing in the descending inhibitory pain pathway.
The changes of cortisol levels in patients with fibromyalgia (FM) are inconsistent in different researches. But the lower levels of cortisol are thought to be due to a maladaptive response to stress resulting from a central abnormality of the hypothalamic-pituitary-adrenal axis (54). The endocannabinoid system is also reported to be altered in animal models of FM. Hong et al. demonstrated a downregulation of CB1 receptor expression in the dorsal root ganglia, whereas, the levels of mRNA expression of AEA and TRPV1 receptors were significantly elevated (55, 56).
Animal models are a useful approach to unravel the complexity of CMPs. Using multiple models to validate a novel therapy or target will allow a better understanding of how these models relate to specific pathological changes in patients with CMP, and how novel therapies can mitigate or prevent these changes (57).
Tendinopathy is a common problem affecting active young and middle-aged people, which has a significant impact on their personal and professional activities (58), even leading to up to 53% of athletes with patellar tendinopathy had to quit their sports career because of knee problem (59). Results of a recent study in a large animal, piglets, showed that ultrasound-guided injection of type 1 collagenase inside the patellar tendon allowed the generation of a tendinopathy model with neovessels in piglets. In addition, the piglets that successfully modeled the pigs showed better tolerance and no suffering sign (60). The significance of this study not only suggests the feasibility of large animals such as piglets in basic research, but also predicts the potential role of type 1 collagenase in the treatment of tendinopathy.
However, there is still a huge gap between basic research and clinical application. One of the most obvious and long-standing differences is gender. As women are two-thirds more likely than men to develop osteoarthritis, and they report greater pain, it's better to use both male and female animals in preclinical OA studies so that sex-specific differences in OA pathogenesis and pain perception can be tease out. However, this point is not well done in current studies, and most basic experiments only use male animals as research objects for various reasons.
In addition, using multiple different methods to measure pain from all aspects in a particular model can assess multiple pain patterns, as well as changes in pain sensation and mechanisms over time. Only by using multiple animal models of OA to understand pain mechanisms can we hope to identify drug and non-drug targets to eliminate this debilitating disease.
Conclusions
In summary, this narrative review briefly summarizes the new classification of diseases (ICD-11). Clinical diagnostic protocols were also summarized, including assessment of pain intensity, patient background and psychological status, functional status, and central sensitization. In addition, on the basis of summarizing the classical treatment options, we introduce the methods involved in the latest research, such as VR and mobile phone based multi-mode analgesia, which would be more suitable for the current COVID-19 epidemic.
Author Contributions
XM and FF conceived the article. JZ and HM revised and reviewed the article. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Perrot S, Cohen M, Barke A, Korwisi B, Rief W, Treede RD, et al. The IASP classification of chronic pain for ICD-11: chronic secondary musculoskeletal pain. Pain. (2019) 160:77–82. doi: 10.1097/j.pain.0000000000001389
2. Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain. (2001) 93:173–83. doi: 10.1016/S0304-3959(01)00314-1
3. Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. (2011) 152:2399–404. doi: 10.1016/j.pain.2011.07.005
4. Mannion AF, Dolan P, Adams MA. Psychological questionnaires: do “abnormal” scores precede or follow first-time low back pain? Spine. (1996) 21:2603–11. doi: 10.1097/00007632-199611150-00010
5. van Dijk GM, Veenhof C, Schellevis F, Hulsmans H, Bakker JP, Arwert H, et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord. (2008) 9:95. doi: 10.1186/1471-2474-9-95
6. Reeuwijk KG, de Rooij M, van Dijk GM, Veenhof C, Steultjens MP, Dekker J. Osteoarthritis of the hip or knee: which coexisting disorders are disabling? Clin Rheumatol. (2010) 29:739–47. doi: 10.1007/s10067-010-1392-8
7. Ethgen O, Vanparijs P, Delhalle S, Rosant S, Bruyere O, Reginster JY. Social support and health-related quality of life in hip and knee osteoarthritis. Qual Life Res. (2004) 13:321–30. doi: 10.1023/B:QURE.0000018492.40262.d1
8. Ferreira VM, Sherman AM. The relationship of optimism, pain and social support to well-being in older adults with osteoarthritis. Aging Ment Health. (2007) 11:89–98. doi: 10.1080/13607860600736166
9. Keefe FJ, Lefebvre JC, Egert JR, Affleck G, Sullivan MJ, Caldwell DS. The relationship of gender to pain, pain behavior, and disability in osteoarthritis patients: the role of catastrophizing. Pain. (2000) 87:325–34. doi: 10.1016/S0304-3959(00)00296-7
10. Lin Q, Bonkano O, Wu K, Liu Q, Ali Ibrahim T, Liu L. The value of chinese version GAD-7 and PHQ-9 to screen anxiety and depression in Chinese outpatients with atypical chest pain. Ther Clin Risk Manag. (2021) 17:423–31. doi: 10.2147/TCRM.S305623
11. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. (2002) 64:258–66. doi: 10.1097/00006842-200203000-00008
12. Goggins J, Baker K, Felson D. What WOMAC pain score should make a patient eligible for a trial in knee osteoarthritis? J Rheumatol. (2005) 32:540–2.
13. Dawson AP, Steele EJ, Hodges PW, Stewart S. Development and test-retest reliability of an extended version of the Nordic Musculoskeletal Questionnaire (NMQ-E): a screening instrument for musculoskeletal pain. J Pain. (2009) 10:517–26. doi: 10.1016/j.jpain.2008.11.008
14. Rolke R, Baron R, Maier C, Tolle TR, Treede DR, Beyer A, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. (2006) 123:231–43. doi: 10.1016/j.pain.2006.01.041
15. Lolignier S, Eijkelkamp N, Wood JN. Mechanical allodynia. Pflugers Arch. (2015) 467:133–9. doi: 10.1007/s00424-014-1532-0
16. Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D, Arden NK, et al. Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical Practice Research Datalink. Osteoarthr Cartil. (2015) 23:594–600. doi: 10.1016/j.joca.2014.12.022
17. National Clinical Guideline Center. Osteoarthritis: Care and Management in Adults. London: National Institute for Health and Care Excellence (2014).
18. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. (2011) 377:2115–26. doi: 10.1016/S0140-6736(11)60243-2
19. Buttgereit F, Burmester GR, Bijlsma JW. Non-surgical management of knee osteoarthritis: where are we now and where do we need to go? RMD Open. (2015) 1:e000027. doi: 10.1136/rmdopen-2014-000027
20. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. (1998) 104: 2S−8S. doi: 10.1016/S0002-9343(97)00203-9
21. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. (2013) 16:821–47. doi: 10.18433/J3VW2F
22. McDougall JJ, Muley M, Reid A, Krustev E. Preventing the onset of inflammation with an endocannabinoid hydrolysis inhibitor alleviates end stage osteoarthritis pain in mice. Osteoarthr Cartil. (2017) 25:S379–S379. doi: 10.1016/j.joca.2017.02.648
23. Schuelert N, Johnson MP, Oskins JL, Jassal K, Chambers MG, McDougall JJ. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. Pain. (2011) 152:975–81. doi: 10.1016/j.pain.2010.11.025
24. Watkins BA, Hutchins H, Li Y, Seifert MF. The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health. J Nutr Biochem. (2010) 21:1141–52. doi: 10.1016/j.jnutbio.2010.04.011
25. Ste-Marie PA, Shir Y, Rampakakis E, Sampalis JS, Karellis A, Cohen M, et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain. (2016) 157:2792–7. doi: 10.1097/j.pain.0000000000000706
26. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Polz W. [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain–a randomized controlled trial]. Wien Klin Wochenschr. (2006) 118:327–35. doi: 10.1016/S1090-3801(06)60627-7
27. Takakuwa KM, Hergenrather JY, Shofer FS, Schears RM. The impact of medical cannabis on intermittent and chronic opioid users with back pain: how cannabis diminished prescription opioid usage. Cannabis Cannabinoid Res. (2020) 5:263–70. doi: 10.1089/can.2019.0039
28. Tan T, Barry P, Reken S, Baker MG. Guideline development: pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. (2010) 340:c1079. doi: 10.1136/bmj.c1079
29. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. (2010) 85(3 Suppl):S3–14 doi: 10.4065/mcp.2009.0649
30. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. (2014) 22:363–88. doi: 10.1016/j.joca.2014.01.003
31. Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral non-steroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. (2011) 27:2361–72. doi: 10.1185/03007995.2011.633502
32. Wang G, Bi L, Li X, Li Z, Zhao D, Chen J, et al. Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study. Osteoarthr Cartil. (2017) 25:832–8. doi: 10.1016/j.joca.2016.12.025
33. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. (2004) 50:2974–84. doi: 10.1002/art.20485
34. Michel MC, Radziszewski P, Falconer C, Marschall-Kehrel D, Blot K. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clin Pharmacol. (2012) 73:821–5. doi: 10.1111/j.1365-2125.2011.04138.x
35. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. (2007) 73:137–50. doi: 10.1016/j.eplepsyres.2006.09.008
36. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. (2020) 396:1711–2. doi: 10.1016/S0140-6736(20)32230-3
37. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. Reston: 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). (2020) 72:149–62. doi: 10.1002/acr.24131
38. DS. Jevsevar. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. (2013) 21:571–6. doi: 10.5435/JAAOS-21-09-571
39. Huizinga J, Stanley E, Song S, Sullivan J, Katz J, Losina E. Direct medical and societal cost of opioid use in symptomatic knee osteoarthritis patients in the United States. Arthritis Rheumatol. (2019) 71.
40. C. Abdel Shaheed Awal W, Zhang G, Gilbert SE, Gallacher D, McLachlan A, Day RO, et al. Efficacy, safety, and dose-dependence of the analgesic effects of opioid therapy for people with osteoarthritis: systematic review and meta-analysis. Med J Aust. (2022) 216:305–11 doi: 10.5694/mja2.51392
41. Lin LL Li YT, Tu JF, Yang JW, Sun N, Zhang S, et al. Effectiveness and feasibility of acupuncture for knee osteoarthritis: a pilot randomized controlled trial. Clin Rehabil. (2018) 32:1666–75. doi: 10.1177/0269215518790632
42. Helianthi DR, Simadibrata C, Srilestari A, Wahyudi ER, Hidayat R. Pain reduction after laser acupuncture treatment in geriatric patients with knee osteoarthritis: a randomized controlled trial. Acta Med Indones. (2016) 48:114–21.
43. Qaseem A, Wilt TJ, McLean RM, Forciea MA P. Clinical Guidelines Committee of the American College of, Denberg TD, et al. Non-invasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. (2017) 166:514–30. doi: 10.7326/M16-2367
44. Ugurlu FG, Sezer N, Aktekin L, Fidan F, Tok F, Akkus S. The effects of acupuncture versus sham acupuncture in the treatment of fibromyalgia: a randomized controlled clinical trial. Acta Reumatol Port. (2017) 42:32–7.
45. Adly AS, Adly AS, Adly MS, Serry ZMH. Laser acupuncture versus reflexology therapy in elderly with rheumatoid arthritis. Lasers Med Sci. (2017) 32:1097–103. doi: 10.1007/s10103-017-2213-y
46. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, polyarticular osteoarthritis. Osteoarthr Cartil. (2019) 27:1578–89. doi: 10.1016/j.joca.2019.06.011
47. Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. Cochrane Database Syst Rev. (2017). doi: 10.1002/14651858.CD011279.pub2
48. Booth J, Moseley GL, Schiltenwolf M, Cashin A, Davies M, Hubscher M. Exercise for chronic musculoskeletal pain: a biopsychosocial approach. Musculoskelet Care. (2017) 15:413–21. doi: 10.1002/msc.1191
49. K. Rausch Osthoff Juhl CB, Knittle K, Dagfinrud H, Hurkmans E, Braun J, et al. Niedermann. Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis. RMD Open. (2018) 4: e000713. doi: 10.1136/rmdopen-2018-000713
50. Smith BE, Hendrick P, Smith TO, Bateman M, Moffatt F, Rathleff MS, et al. Should exercises be painful in the management of chronic musculoskeletal pain? A systematic review and meta-analysis. Br J Sports Med. (2017) 51:1679. doi: 10.1136/bjsports-2016-097383
51. Gwinnutt JM, Wieczorek M, Cavalli G, Balanescu A, Bischoff-Ferrari HAA. Boonen,de Souza SA, et al. Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. (2022) 8:e002168. doi: 10.1136/rmdopen-2021-002168. [Epub ahead of print].
52. Morcillo-Munoz Y, Sanchez-Guarnido AJ, Calzon-Fernandez S, Baena-Parejo I. Multimodal chronic pain therapy for adults via smartphone: randomized controlled clinical trial. J Med Internet Res. (2022) 24:e36114. doi: 10.2196/36114
53. Stamm O, Dahms R, Reithinger N, Russ A, Muller-Werdan U. Virtual reality exergame for supplementing multimodal pain therapy in older adults with chronic back pain: a randomized controlled pilot study. Virtual Real. (2022):1–15. doi: 10.1007/s10055-022-00629-3. [Epub ahead of print].
54. Lin YJ, Ko YC, Chow LH, Hsiao FJ, Liu HY, Wang PN, et al. Salivary cortisol is associated with cognitive changes in patients with fibromyalgia. Sci Rep. (2021) 11:1311. doi: 10.1038/s41598-020-79349-0
55. Hong S, Fan J, Kemmerer ES, Evans S, Li Y, Wiley JW. Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut. (2009) 58:202–10. doi: 10.1136/gut.2008.157594
56. Hong S, Zheng G, Wu X, Snider NT, Owyang C, Wiley JW. Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology. (2011) 140:627–637 e4. doi: 10.1053/j.gastro.2010.11.003
57. O'Brien M, Philpott HT, McDougall JJ. Understanding osteoarthritis pain through animal models. Clin Exp Rheumatol. (2017) 35:S47–52.
58. Dominick KL, Ahern FM, Gold CH, Heller DA. Health-related quality of life and health service use among older adults with osteoarthritis. Arthritis Rheum. (2004) 51:326–31. doi: 10.1002/art.20390
59. Kettunen JA, Kvist M, Alanen E, Kujala UM. Long-term prognosis for jumper's knee in male athletes. A prospective follow-up study. Am J Sports Med. (2002) 30:689–92. doi: 10.1177/03635465020300051001
Keywords: musculoskeletal pain, classification, diagnosis, management, advances
Citation: Zhuang J, Mei H, Fang F and Ma X (2022) What Is New in Classification, Diagnosis and Management of Chronic Musculoskeletal Pain: A Narrative Review. Front. Pain Res. 3:937004. doi: 10.3389/fpain.2022.937004
Received: 05 May 2022; Accepted: 20 June 2022;
Published: 15 July 2022.
Edited by:
Xu Jin, Capital Medical University, ChinaReviewed by:
Chen Su, Central South University, ChinaHuichao Zou, Harbin Medical University Cancer Hospital, China
Copyright © 2022 Zhuang, Mei, Fang and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fang Fang, fang_fang0604@163.com; Xiaqing Ma, zxymxq@163.com
†These authors have contributed equally to this work